Bone Biologics Corp (BBLGW) Amortization of Deferred Charges (2015 - 2018)

Bone Biologics (BBLGW) has reported Amortization of Deferred Charges for 4 consecutive years, with $1694.0 the latest figure, recorded in Q3 2018.

• In Q3 2018, Amortization of Deferred Charges fell 82.71% year-over-year to $1694.0; the TTM figure through Dec 2019 stood at $1694.0 (down 92.04% YoY), while the FY2018 annual figure was $21283.0, down 45.67% from the prior year.
• Amortization of Deferred Charges declined to $1694.0 in Q3 2018 per BBLGW's latest filing, from $9795.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $414917.0 in Q1 2015 and bottomed at $1694.0 in Q3 2018.
• Historically, Amortization of Deferred Charges has averaged $51804.9 across 4 years, with a median of $9795.0 in 2017.
• Annual changes were most pronounced in 2016 — Amortization of Deferred Charges plunged 93.83% — and 2017, when it rose 0.02%.
• Bone Biologics' Amortization of Deferred Charges stood at $61836.0 in 2015, then plunged by 84.16% to $9796.0 in 2016, then fell by 0.02% to $9794.0 in 2017, then sank by 82.7% to $1694.0 in 2018.
• Business Quant data shows BBLGW's Amortization of Deferred Charges at $1694.0 in Q3 2018, $9795.0 in Q2 2018, and $9794.0 in Q1 2018.